<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03700918</url>
  </required_header>
  <id_info>
    <org_study_id>CLP-001</org_study_id>
    <nct_id>NCT03700918</nct_id>
  </id_info>
  <brief_title>First in Human Study of the DaVingi™ TR System in the Treatment of Patients With Functional Tricuspid Regurgitation</brief_title>
  <official_title>A First in Human Study to Assess Safety and Performance of the DaVingi™ System in the Treatment of Patients With Functional Tricuspid Regurgitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiac Implants LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiac Implants LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The DaVingi™ System is a percutaneous trans-catheter device delivered using right heart&#xD;
      catheterization through the right internal jugular vein. The DaVingi™ System is designed for&#xD;
      performing ring annuloplasty by using a Ring Delivery System to place a complete, flexible&#xD;
      fabric ring around the annulus of the atrial side of the tricuspid valve. Fluoroscopy and&#xD;
      echocardiography are used to monitor the ring placement procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The annuloplasty ring is a small multi-element ring, consisting of an outer fabric layer, a&#xD;
      pre-set stakes array and internal adjustment cord that can be adjusted at a later stage after&#xD;
      the outer layer of the ring and stakes are encapsulated in new tissue growth. Once implanted,&#xD;
      the ring is designed to serve as a foundation for promoting new annular tissue growth,&#xD;
      effectively growing a new adjustable annulus around the valve.&#xD;
&#xD;
      the study has been approved by Institutional Review Boards and Competent Authorities in Czech&#xD;
      Republic, France and Israel.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2017</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>First in human</intervention_model_description>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety- the incidence and severity of device-related serious adverse device effects (SADE)</measure>
    <time_frame>from time of index implant/ adjustment procedure through 30 days post-implant</time_frame>
    <description>the incidence and severity of device-related serious adverse device effects (SADE) from time of index implant/ adjustment procedure through 30 days post-implant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Device performance - Adjustment Device Technical Success: Rate of successful adjustment of the DaVingi™ TR ring at the tricuspid annulus, desired by physician</measure>
    <time_frame>Immediately after procedure</time_frame>
    <description>Implant Device Technical Success and Adjustment Device Technical Success</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety - Incidence of device-related major adverse cardiac events (MACE)</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>Incidence of device-related major adverse cardiac events (MACE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety - Rate of procedure-related serious adverse events (SAE)</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>Rate of procedure-related serious adverse events (SAE)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Functional Tricuspid Regurgitation (TR)</condition>
  <arm_group>
    <arm_group_label>DaVingiTR System Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single-arm, open label, multi-center study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DaVingiTR System</intervention_name>
    <description>DaVingiTR Tricuspid valve annuloplasty repair device</description>
    <arm_group_label>DaVingiTR System Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Severe tricuspid regurgitation as defined by American Society of Echocardiography.&#xD;
&#xD;
          2. Symptoms of right ventricular failure despite appropriate medical therapy.&#xD;
&#xD;
          3. Multidisciplinary heart team (minimum of three physicians, including cardiology and&#xD;
             cardiac surgery representatives) recommends tricuspid annuloplasty.&#xD;
&#xD;
          4. ≥18 years old at time of enrollment.&#xD;
&#xD;
          5. LVEF ≥ 30% within 45 days prior to index implant procedure.&#xD;
&#xD;
          6. PASP &lt; 70 mmHg via right heart catheterization (subject at rest) within 90 days prior&#xD;
             to index implant procedure.&#xD;
&#xD;
          7. Right Ventricle TAPSE ≥ 13 mm within 45 days prior to index implant procedure.&#xD;
&#xD;
          8. Tricuspid valve annular diameter ≥ 40 mm as measured by baseline transthoracic&#xD;
             echocardiography in the 4 chamber view within 45 days prior to index implant&#xD;
             procedure.&#xD;
&#xD;
          9. Subject has provided written informed consent.&#xD;
&#xD;
         10. Subject agrees to comply with all required post-procedure follow-up visits, including&#xD;
             device adjustment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acutely decompensated heart failure (i.e. hemodynamically unstable or on IV&#xD;
             inotropes).&#xD;
&#xD;
          2. Severe Right Ventricle dysfunction.&#xD;
&#xD;
          3. Primary tricuspid pathology (e.g. rheumatic, congenital, infective, etc.).&#xD;
&#xD;
          4. Previous tricuspid valve repair or replacement.&#xD;
&#xD;
          5. Transvalvular pacemaker or defibrillator lead is present.&#xD;
&#xD;
          6. Severe left-sided valve disease.&#xD;
&#xD;
          7. Right-sided intra-cardiac mass, thrombus or vegetation is present.&#xD;
&#xD;
          8. Inability to properly guide the index implant procedure using Trans-esophagus&#xD;
             echocardiography (e.g. acoustic window not adequate).&#xD;
&#xD;
          9. Subject requires chronic dialysis or renal replacement therapy.&#xD;
&#xD;
         10. MI or known unstable angina within the 30-days prior to the implant index procedure.&#xD;
&#xD;
         11. CVA within 3 months prior to index implant procedure.&#xD;
&#xD;
         12. Bleeding disorders, active peptic ulcer or GI bleed.&#xD;
&#xD;
         13. Contraindication to anticoagulation or antiplatelet medication, based on&#xD;
             investigator's opinion.&#xD;
&#xD;
         14. Chronic oral steroid or immunomodulator use (≥ 6 months) or other condition that could&#xD;
             impair healing response (e.g. cardiac sarcoidosis or other chronic inflammatory&#xD;
             disease).&#xD;
&#xD;
         15. Any condition that, in the opinion of the investigator, may render the subject unable&#xD;
             to complete the study (life expectancy &lt; 1 year), or lead to difficulties for subject&#xD;
             compliance with study requirements.&#xD;
&#xD;
         16. Subject is enrolled in another investigational study which has not completed the&#xD;
             required primary endpoint follow-up period (Note: patients involved in a long-term&#xD;
             surveillance phase of another study are eligible for this study).&#xD;
&#xD;
         17. Female patients who are pregnant or lactating.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nodar Kipshidze, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Cardiac Implants LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nodar Kipshidze, MPH</last_name>
    <phone>1-917-370-6247</phone>
    <email>Nodar@cardiac-implants.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Na Homolce Hospital</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petr Moucka, Mgr</last_name>
      <phone>+420257272392</phone>
      <email>Petr.Moucka@homolka.cz</email>
    </contact>
    <investigator>
      <last_name>Petr Neuzil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Bichat</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reza Farnoud, Dr.</last_name>
      <email>reza.farnoud.bch@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Marina Urena Alcazar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Imane Bagdadi</last_name>
      <email>Imane.Bagdadi@imm.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe Caussin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederic Petit</last_name>
      <email>fpetit@clinique-pasteur.com</email>
    </contact>
    <investigator>
      <last_name>Didier Tchétché, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ludmila Helmer</last_name>
      <phone>+97247772180</phone>
      <email>l_helmer@rambam.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Kerner Arthur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>France</country>
    <country>Israel</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 31, 2017</study_first_submitted>
  <study_first_submitted_qc>October 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

